Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Abstract Background Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is triggered by nCOV-19 adenovirus-vectored vaccines against SARS-CoV2. Pathogenesis has been mainly related to platelet activation via PF4-reactive antibodies that activate platelets and may cross-react with heparin....
Main Authors: | Lasse Myllylahti, Hanna Pitkänen, Harry Magnani, Riitta Lassila |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-02-01
|
Series: | Thrombosis Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12959-021-00362-y |
Similar Items
-
COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes
by: Gewil Daniella Olipas Allas, et al.
Published: (2022-12-01) -
Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)—Insights from Clinical Cases, In Vitro Studies and Murine Models
by: Venkata A. S. Dabbiru, et al.
Published: (2023-09-01) -
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
by: Takehiro Hayashi, et al.
Published: (2019-12-01) -
Usefulness of Danaparoid sodium in patients with Heparin-induced thrombocytopenia after cardiac surgery
by: Farzaneh Foroughinia, et al.
Published: (2015-01-01) -
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)
by: Michael Makris, et al.
Published: (2021-07-01)